BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 22, 2019
View Archived Issues
FDA accepts IND application for ST-920 gene therapy candidate for Fabry disease
Read More
Gamida Cell presents clinical data from the NAM-NK and NiCord programs
Read More
Foresee reports topline phase III data on FP LMIS for prostate cancer
Read More
Transcriptional pathways behind the enhanced bactericidal and lysosomal properties of MPB
Read More
Ultragenyx presents positive 24-week data from first cohort of phase I/II study of DTX-401
Read More
Guangdong Zhongsheng Pharmaceutical initiates two phase I trials in patients with solid tumors
Read More
Nonmyeloablative conditioning vs. head-shielded irradiation to study brain tumor-immune interaction
Read More
Development of a novel quadruple agonist to treat nonalcoholic steatohepatitis and fibrosis
Read More
Imarikiren improves albuminuria in patients with type 2 diabetes
Read More
The European Commission grants approval for Besremi for the treatment of polycythemia vera
Read More
Abbisko Therapeutics divulges new FGFR4 inhibitors
Read More
Alphala presents new compounds for cancer
Read More
CCR5 receptor has role in stroke recovery
Read More
Bristol-Myers Squibb identifies TLR7/8/9 antagonists
Read More
Morphic Therapeutic and Janssen to collaborate on integrin therapeutics
Read More
Humira becomes the first treatment in Japan to be approved for hidradenitis suppurativa
Read More
Theravance Biopharma discloses JAK3 inhibitors
Read More
Agios Pharmaceuticals initiates phase I study of AG-636 in advanced lymphoma
Read More
Calithera initiates phase I study of the arginase inhibitor CB-280
Read More
Zeno Royalties & Milestones divulges WEE1hu inhibitors
Read More
Phase II study of OPNT-001 in bulimia nervosa does not meet primary endpoint
Read More
DEGS1 loss seen to cause hypomyelinating leukodystrophy
Read More
Durable responses seen with sacituzumab govitecan in metastatic triple-negative breast cancer
Read More
GSE-4 peptide ameliorates oxidative stress, telomere deficiency in ataxia telangiectasia
Read More